Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Joseph A Prendiville"'
Autor:
Brian W Fox, Gordon C Jayson, Derek Crowther, George R. Pettit, Peter L. Stern, Joseph A Prendiville, Christof Scheid
Publikováno v:
Cancer Immunology Immunotherapy. 39:223-230
Bryostatin 1 is a protein kinase C activator that inhibits growth of tumour cells and activates lymphocytes in vitro, properties that have encouraged its use in phase 1 clinical studies as an anticancer agent. We investigated interleukin-2(IL-2)-indu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ec4851f47c1f317da653b5267fd66fc
https://doi.org/10.1007/bf01525985
https://doi.org/10.1007/bf01525985
Publikováno v:
International Journal of Gynecologic Cancer. 4:200-205
Carcinosarcomas (previously termed malignant mixed Müllerian tumors) are highly malignant but rare tumors of the ovary. Most patients have been treated according to a wide variety of protocols for soft tissue sarcoma or for epithelial ovarian carcin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72025a3c2323e67694d7a8ec31c536ec
https://doi.org/10.1046/j.1525-1438.1994.04030200.x
https://doi.org/10.1046/j.1525-1438.1994.04030200.x
Autor:
Malcolm R Ranson, Michael J. Lind, V R Tindall, D Murphy, J Renninson, C. H. Buckley, Mark Dougal, U Patel, Joseph A Prendiville, Derek Crowther
Publikováno v:
Annals of Oncology. 4:377-383
Summary Background The importance of dose intensity has not been clearly defined in ovarian cancer and we present a prospectively randomised trial of dose intensity in patients with ovarian cancer. Patients and methods Ninety-nine patients with FIGO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ea706c88952658a3ff19c05db22d29f
https://doi.org/10.1093/oxfordjournals.annonc.a058516
https://doi.org/10.1093/oxfordjournals.annonc.a058516
Autor:
Derek Crowther, Parveen Khan, Joseph A Prendiville, George R. Pettit, Martin J Dawson, Gordon C Jayson, Alan T McGown
Publikováno v:
Europe PubMed Central
An HPLC assay incorporating a solid-phase extraction technique has been devised for bryostatin-1. Quantitation of bryostatin was found to be linear over the concentration range 0.012-25 microg/ml (0.2-25 ng on column) and was found to have a limit of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74da1f943cb6aed36d127cc5f813399e
https://pubmed.ncbi.nlm.nih.gov/9653932
https://pubmed.ncbi.nlm.nih.gov/9653932
Autor:
Alan T McGown, Andreas J. Gescher, Derek Crowther, Joseph A Prendiville, A J Dickson, C Courage, George R. Pettit, Brian W Fox
Publikováno v:
British Journal of Cancer
Bryostatin 1 is a novel macrocyclic lactone activator of protein kinase C (PKC) which has clinical potential as an anti-cancer agent. The mechanism of action of this agent is unknown, but protein kinase C has been implicated. In order to investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f65a73fc8de70d8b263b7ec68793e179
https://pubmed.ncbi.nlm.nih.gov/7917900
https://pubmed.ncbi.nlm.nih.gov/7917900
Autor:
Nick Thatcher, Peter L. Stern, R McIntosh, Anna K Ghosh, Michael J. Lind, Joseph A Prendiville, Derek Crowther
Publikováno v:
European journal of cancer (Oxford, England : 1990). (12)
19 patients with advanced cancer were entered into a phase I study of recombinant human interleukin-4 (rhu IL-4). The predominant clinical side-effects included flu-like symptoms, gastrointestinal upset, lethargy and transient hypotension. In additio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fab51b6d4d1a50827fb92ae4bf072943
https://pubmed.ncbi.nlm.nih.gov/8398297
https://pubmed.ncbi.nlm.nih.gov/8398297
Autor:
James P. Stewart, John R. Arrand, Joseph A Prendiville, Brian W Fox, George R. Pettit, Alan T McGown
Publikováno v:
Cancer chemotherapy and pharmacology. 33(1)
Bryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the produc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8f995bb779cd1c287c79f7284940f18
https://pubmed.ncbi.nlm.nih.gov/8269596
https://pubmed.ncbi.nlm.nih.gov/8269596
Publikováno v:
Cancer chemotherapy and pharmacology. 29(3)
The stability of cisplatin (DDP) solutions (1 and 1.6 mg/ml in saline-mannitol) in plastic infusion bags was studied for up to 14 days at 25 degrees C, 37 degrees C and 60 degrees C. Small changes in the solution were observed, but no evidence of any
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65ccff329858c55549c204e8f0146ea2
https://pubmed.ncbi.nlm.nih.gov/1733559
https://pubmed.ncbi.nlm.nih.gov/1733559
Autor:
J Renninson, Michael J. Lind, G. Thompson, Joseph A Prendiville, D.R. Smith, D Murphy, Derek Crowther, Malcolm R Ranson
Publikováno v:
European journal of cancer (Oxford, England : 1990). (4-5)
13 patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian cancer were treated with intraperitoneal iproplatin. A total of three cycles were given at monthly intervals. All patients had minimal residual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e83c478d5647fcc9ace1587d0c9ee16f
https://pubmed.ncbi.nlm.nih.gov/1524912
https://pubmed.ncbi.nlm.nih.gov/1524912
Autor:
Nick Thatcher, William P. Steward, Paul A Burt, John Radford, Joseph A Prendiville, Ronald Stout, Malcolm R Ranson
Publikováno v:
ResearcherID
Scopus-Elsevier
University of Manchester-PURE
Scopus-Elsevier
University of Manchester-PURE
Forty patients with small-cell lung cancer (31 patients with limited-stage [LS] disease, and nine patients with extensive-stage [ES] disease but of good performance status) have been treated with an intensive therapy composed of carboplatin alternati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97c3ec8f6b614b700952e6b87504bfb8
https://pubmed.ncbi.nlm.nih.gov/1649266
https://pubmed.ncbi.nlm.nih.gov/1649266